ECM
DMAC icon

ExodusPoint Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

ExodusPoint Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,011
Closed -$406K – 1672
2026
Q1 		$406K Buy
+60,011
New +$476K ﹤0.01% 1240
2025
Q2 		– Sell
-13,343
Closed -$51K – 1578
2025
Q1 		$51K Buy
+13,343
New +$76.3K ﹤0.01% 1370
2021
Q1 		– Sell
-13,160
Closed -$133K – 2212
2020
Q4 		$133K Buy
+13,160
New +$72K ﹤0.01% 1799

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ExodusPoint Capital Management's DMAC Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 60,011 shares — an estimated $406K sold.

ExodusPoint Capital Management first reported a position in DMAC in Q4 2020 and held it in 3 quarters. The position peaked at $406K in Q1 2026. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • ExodusPoint Capital Management reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 60,011 DiaMedica Therapeutics shares in Q2 2026, an estimated $406K.
  • ExodusPoint Capital Management first reported a position in DiaMedica Therapeutics in Q4 2020 and held it in 3 quarters.
  • ExodusPoint Capital Management's DiaMedica Therapeutics position peaked at $406K in Q1 2026.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.